Journal of Clinical Pediatrics >
Clinical characteristics and genotype analysis of adenosine deaminase 2 (ADA2) deficiency in China: a report of three cases
Received date: 2022-07-13
Online published: 2024-02-02
Objective To summarise the clinical features and genotypic characteristics of three children with adenosine deaminase 2 (ADA2) deficiency and to improve understanding of the disease. Methods The clinical features of three children with ADA2 deficiency were retrospectively analysed and genetically analysed using exome sequencing (ES). The activity of ADA2 enzyme in the plasma of the patients was measured using a kit. The clinical and genotypic features of the disease were summarised. Results All three children in our group had ADA2 gene variants. Case 1 had recurrent fever, rash, and convulsions as the main clinical manifestations, combined with stroke, accompanied by markedly elevated inflammatory indexes, and there were compound heterozygous variants in the ADA2 gene: c.139G>T and c.484T>C variants. Case 2 had recurrent fever and rash as the main clinical manifestations, combined with gastrointestinal perforation and stroke during the course of the disease, with markedly elevated inflammatory indexes. ES identified compound heterozygous variants of c.916C>T and c.1069G>A in the ADA2 gene. In Case 3, the patient had recurrent fever and cough as the main clinical manifestations, combined with myocarditis, accompanied by markedly reduced immune function. ES identified c.849T>G homozygous variants in ADA2 gene; Plasma ADA2 enzyme activity was found to be significantly reduced in case 1 and 2. Conclusion ADA2 deficiency is rare in China, with variable clinical features, and mastering its clinical features and genetic characteristics can help improve the diagnosis level.
Key words： adenosine deaminase type 2 deficiency; ADA2 gene; gene mutation; child
Yang ZHOU , Yali WU , Yan DING . Clinical characteristics and genotype analysis of adenosine deaminase 2 (ADA2) deficiency in China: a report of three cases[J]. Journal of Clinical Pediatrics, 2024 , 42(2) : 116 -120 . DOI: 10.12372/jcp.2024.22e0958
| [1] | Pinto B, Deo P, Sharma S, et al. Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment[J]. Clin Rheumatol, 2021, 40(10): 3883-3896. |
| [2] | Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2[J]. N Engl J Med, 2014, 370(10): 911-920. |
| [3] | Zhang B, Sun Y, Xu N, et al. Adult-onset deficiency of adenosine deaminase 2—a case report and literature review[J]. Clinical Rheumatology, 2021, 40(10): 4325-4339. |
| [4] | 张冰清, 张硕, 王涛, 等. 第544例结节红斑—血小板减少—青斑样血管病—免疫缺陷[J]. 中华医学杂志, 2021, 101(31): 2485-2487. |
| [5] | 柏翠, 郭兴青, 高婷婷, 等. 儿童腺苷脱氨酶2缺乏症2例并文献复习[J]. 中华实用儿科临床杂志, 2020, 35(21): 1674-1677. |
| [6] | Human A, Pagnoux C. Diagnosis and management of ADA2 deficient polyarteritis nodosa[J]. Int J Rheum Dis, 2019, 22 (Suppl 1): 69-77. |
| [7] | Fayand A, Chasset F, Boutboul D, et al. DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases[J]. Semin Arthritis Rheum, 2021, 51(6): 1170-1179. |
| [8] | Meyts I, Aksentijevich I. Deficiency of Adenosine Deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment[J]. J Clin Immunol, 2018, 38(5): 569-578. |
| [9] | Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study[J]. Ann Rheum Dis, 2017, 76(10): 1648-1656. |
| [10] | Caratsch L, Schnider C, Moi L, et al. Adenosine deaminase 2 deficiency: a disease with multiple presentations[J]. Rev Med Suisse, 2022, 18(776): 669-673. |
| [11] | Sharma A, Naidu G, Sharma V, et al. Deficiency of adenosine deaminase 2 in adults and children: experience from India[J]. Arthritis Rheumatol, 2021, 73(2): 276-285. |
| [12] | Nanthapisal S, Murphy C, Omoyinmi E, et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases[J]. Arthritis Rheumatol, 2016, 68(9): 2314-2322. |
| [13] | Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, et al. ADA2 deficiency mimicking idiopathic multicentric castleman disease[J]. Pediatrics, 2018, 142(3): e20172266. |
| [14] | Van Montfrans JM, Hartman EA, Braun KP, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations[J]. Rheumatology (Oxford), 2016, 55(5): 902-910. |
| [15] | Westendorp WF, Nederkoorn PJ, Aksentijevich I, et al. Unexplained early-onset lacunar stroke and inflammatory skin lesions: Consider ADA2 deficiency[J]. Neurology, 2015, 84(20): 2092-2093. |
| [16] | Batu ED, Karadag O, Taskiran EZ, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations[J]. J Rheumatol, 2015, 42(8): 1532-1534. |
| [17] | Uettwiller F, Sarrabay G, Rodero MP, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters[J]. RMD Open, 2016, 2(1): e000236. |
| [18] | Schena F, Penco F, Volpi S, et al. Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients[J]. Eur J Immunol, 2021, 51(1): 206-219. |
| [19] | Lee PY, Kellner ES, Huang Y, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)[J]. J Allergy Clin Immunol, 2020, 145(6): 1664-1672. |
| [20] | ?zen S, Batu ED, Ta?k?ran EZ, et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2[J]. J Rheumatol, 2020, 47(1): 117-125. |
| [21] | Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy[J]. N Engl J Med, 2014, 370(10): 921-931. |
| [22] | Van Eyck L Jr., Hershfield MS, Pombal D, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency[J]. J Allergy Clin Immunol, 2015, 135(1): 283-287. |
| [23] | Garg N, Kasapcopur O, Foster J, 2nd, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy[J]. Eur J Pediatr, 2014, 173(6): 827-830. |
| [24] | 郭莉, 卢美萍. 腺苷脱氨酶2缺乏症研究进展[J]. 中华儿科杂志, 2020, 58(6): 520-523. |
| [25] | Zhang B, Xu N, Chen J, et al. Treatment and outcome in deficiency of adenosine deaminase 2: a literature review[J]. J Investig Allergol Clin Immunol, 2021, 32(1): 13-22. |
| [26] | Ombrello AK, Qin J, Hoffmann PM, et al. Treatment strategies for deficiency of adenosine deaminase 2[J]. The New England journal of medicine, 2019, 380(16): 1582-1584. |
| [27] | Gibson KM, Morishita KA, Dancey P, et al. Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis[J]. Arthritis Rheumatol, 2019, 71(10): 1747-1755. |
| [28] | Lee PY. Vasculopathy, Immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2[J]. Front Pediatr, 2018, 6: 282. |
/
| 〈 |
|
〉 |
